Clinical Trials Browser

Withdrawn × Breast × Clear all

NCT03804255 2026-05-06

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT07134556 2026-05-01

ADJUNCT

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02856503 2026-04-17

Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors

Phase 1/2 Withdrawn

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07475923 2026-04-16

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Breast Neoplasms

NCT05664893 2026-04-15

CALHYS

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

NCT06229392 2026-03-11

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms, Influenza, Human, Triple Negative Breast Neoplasms

NCT03868475 2026-03-09

VAPEX

Phase NA Withdrawn

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Cicatrix, Phyllodes Tumor, Patient Satisfaction, Fibroadenoma

NCT06710197 2026-03-05

OZM-034

Phase 2 Withdrawn

Early Stage Triple Negative ER Low Breast Cancer

NCT07439432 2026-02-27

Stereotactic Guided Biopsy and Cryoablation

Phase NA Withdrawn

Breast Neoplasms

NCT05014295 2026-02-24

Patient Recall of Cancer Screening and Diagnosis

Phase NA Withdrawn

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT05512260 2026-02-11

BESTa

Phase NA Withdrawn

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Phase 1/2 Withdrawn

HER2-positive Breast Cancer

NCT07226102 2026-02-04

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

Phase NA Withdrawn

BreastGynecologic

Genital Neoplasms, Female, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT05957042 2025-12-10

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT07150767 2025-12-02

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

Phase 1 Withdrawn

Locally Advanced Breast Cancer (LABC)

NCT07076680 2025-11-28

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Breast Cancer Metastatic

NCT07092475 2025-11-26

The Impact of Intraoperative Methadone on Postoperative Opioid Use

Phase 3 Withdrawn

Breast Neoplasms

NCT02825810 2025-11-18

Cervical Motor Control in Long-term Breast Cancer Survivors

Phase NA Withdrawn

Breast Neoplasms, Neck Pain

NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT04794816 2025-10-14

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care

Breast Neoplasms

NCT06884254 2025-10-14

EGC102

Phase 3 Withdrawn

Breast Neoplasms

NCT03974204 2025-09-26

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Phase NA Withdrawn

Breast Neoplasms, Meningeal Carcinomatosis

NCT06597773 2025-09-26

Online Patient Navigation Program for Patients With Breast Cancer

Phase NA Withdrawn

Breast Neoplasms

NCT06672224 2025-09-17

Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema

Phase NA Withdrawn

Breast Cancer Lymphedema, Breast Neoplasms

NCT01827969 2025-09-16

USF

Phase NA Withdrawn

Breast Neoplasms

NCT00466830 2025-09-11

SDPM

Breast Neoplasms, Pain

NCT00210145 2025-09-04

ASE K SEIN

Breast Neoplasms

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT05678205 2025-07-30

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Phase 1/2 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06246786 2025-07-16

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT06852560 2025-06-26

GEM

Phase NA Withdrawn

Breast Neoplasms, Atherosclerosis

NCT03941223 2025-06-25

Regional Anesthesia for Breast Surgery

Phase NA Withdrawn

Breast Neoplasms

NCT06494046 2025-06-04

Defining Musical Toxicity and Its Effect on Patient Well-being

BreastCNSGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms

NCT05990478 2025-05-21

A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer

Breast Neoplasms

NCT06145399 2025-05-18

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms

NCT06978478 2025-05-18

IMETAB6

Phase NA Withdrawn

Breast Neoplasms

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT06008301 2025-04-30

Comparing Breast Magnetic Resonance Imaging (MRI) and Contrast-enhanced Mammography (CEM)

Phase NA Withdrawn

Breast Cancer Female

NCT04418219 2025-04-29

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT05940844 2025-04-09

Study of OB-002 in Patients With Refractory Metastatic Cancer

Phase 1 Withdrawn

BreastGastrointestinalGenitourinary

Breast Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04889495 2025-03-19

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Kidney Neoplasms, Colorectal Neoplasms

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms